VIDEO: Implications of SOLOIST, SCORED trials for heart failure treatment in diabetes
Click Here to Manage Email Alerts
In this video exclusive, Richard E. Pratley, MD, talks with Deepak L. Bhatt, MD, MPH, about results and implications of the SOLOIST and SCORED trials of the SGLT1/SGLT2 inhibitor sotogliflozin vs. placebo in adults with type 2 diabetes.
Pratley is the Samuel E. Crockett Chair in Diabetes Research and medical director of AdventHealth Diabetes Institute, and Bhatt is executive director of interventional cardiology programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School.
The SOLOIST and SCORTED study populations were patients with acute decompensated heart failure and with chronic kidney disease, respectively. Pooled data demonstrated significant reduction in CV death, HF hospitalization and urgent HF visits across the range of ejection fraction with sotagliflozin.
Pratley and Bhatt discuss the role of SGLT1 inhibition in the results and whether SGLT2 inhibitors should be initiated in the hospital for appropriate patients.
Collapse
Click Here to Manage Email Alerts